Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
Titel:
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
Auteur:
Goetz, M.P. Bagegni, N.A. Batist, G. Brufsky, A. Cristofanilli, M.A. Damodaran, S. Daniel, B.R. Fleming, G.F. Gradishar, W.J. Graff, S.L. Grosse Perdekamp, M.T. Hamilton, E. Lavasani, S. Moreno-Aspitia, A. O’Connor, T. Pluard, T.J. Rugo, H.S. Sammons, S.L. Schwartzberg, L.S. Stover, D.G. Vidal, G.A. Wang, G. Warner, E. Yerushalmi, R. Plourde, P.V. Portman, D.J. Gal-Yam, E.N.